HedgeCo.Net — Basecamp Research, a London- and Boston-area AI therapeutics company, closed an oversubscribed $140 million Series C led by S32, according to a September 2026 company release carried on PR Newswire and Genetic Engineering & Biotechnology News. Participants include NVIDIA, Menlo Ventures’ Anthology Fund, Catalio Capital Management, True Ventures, the NATO Innovation Fund, The Rockefeller Foundation and others named in the release.
Proceeds will train next-generation EDEN biological foundation models and advance a pipeline of AI-designed therapeutics beginning with in vivo cell therapy. Andy Conrad, general partner at S32 and former Verily CEO, is joining the board. The company is headquartered in London with offices and labs in Cambridge, Massachusetts.
The company release does not state a valuation; secondary coverage, including an MSN-syndicated report, put the post-round valuation around $800 million. Prior financings cited in GEN coverage include a $60 million Series B in 2024 and a $20 million Series A two years earlier.
For biotech-AI allocators, the hard marks are the $140 million S32-led Series C, named strategic/financial participants, EDEN/in vivo cell-therapy use of proceeds, London–Boston footprint, and the ~$800 million valuation mark only as secondary-coverage — not a company-stated figure.